Equities

JW (Cayman) Therapeutics Co Ltd

JW (Cayman) Therapeutics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.37
  • Today's Change0.13 / 10.48%
  • Shares traded1.13m
  • 1 Year change-31.84%
  • Beta1.8321
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0061,3831,834
Total Receivables, Net0292.86
Total Inventory465639
Prepaid expenses------
Other current assets, total161619
Total current assets1,0671,4851,895
Property, plant & equipment, net343394381
Goodwill, net------
Intangibles, net711894816
Long term investments------
Note receivable - long term137.2313
Other long term assets4.644.594.57
Total assets2,1462,7913,117
LIABILITIES
Accounts payable3.277.602.57
Accrued expenses517588
Notes payable/short-term debt000
Current portion long-term debt/capital leases12115320
Other current liabilities, total897588
Total current liabilities264311199
Total long term debt198126127
Total debt319279147
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities462437326
SHAREHOLDERS EQUITY
Common stock0.030.030.03
Additional paid-in capital6,0816,0816,081
Retained earnings (accumulated deficit)(4597)(3864)(3100)
Treasury stock - common0.000.000.00
Unrealized gain (loss)------
Other equity, total200137(190)
Total equity1,6842,3542,791
Total liabilities & shareholders' equity2,1462,7913,117
Total common shares outstanding412411408
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.